soul trial oral semaglutide cardiovascular outcomes 2024 results nejm (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine NEJM Editorial Fellow Harleen Marwah,

But even if the medication is approved, its still quite expensive

Pay with the Klarna app at BioTRUST

At Formation, every peptide protocol starts with a thorough evaluation to determine whether BPC-157 is appropriate for your specific goals and health profile

Hybye C, Biller BMK, Ferran JM, Gordon MB, Kelepouris N, Nedjatian N, et al

Persistent or excessive urination should be medically evaluated, particularly if it is accompanied by thirst, dizziness, or signs of dehydration

And since the May 2025 deadline has already passed, healthcare professionals recommend acting now rather than waiting until your supply runs out